ClinicalTrials.gov
ClinicalTrials.gov Menu

Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00709137
Recruitment Status : Withdrawn (lack of enrollment)
First Posted : July 3, 2008
Last Update Posted : May 28, 2014
Sponsor:
Information provided by (Responsible Party):
Richard Rose, VA Salt Lake City Health Care System

July 1, 2008
July 3, 2008
May 28, 2014
October 2008
October 2010   (Final data collection date for primary outcome measure)
Dose titration of spironolactone and amiloride will cease once the ABPM study reveals a goal 24 hour mean BP below 130/80 in the general hypertensive patients or below 120/70 in patients with diabetes mellitus or chronic kidney disease (eGFR < 60) [ Time Frame: 2-6 months ]
Same as current
Complete list of historical versions of study NCT00709137 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension
Randomized Trial of Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension
Joint National Committee 7 (JNC-7) defines resistant hypertension as a persistent elevation of blood pressure (BP) above goal - ≥ 140/90 mm Hg for the general hypertensive population or ≥ 130/80 mm Hg for persons with diabetes mellitus or chronic kidney disease - for at least three months despite treatment with three or more optimally dosed antihypertensive agents, including a diuretic. The exact prevalence of resistant hypertension is uncertain but may include 5-20% of hypertensive persons in primary care settings and 15-35% of the older, higher cardiovascular risk hypertensive patients incorporated into recent clinical trials of antihypertensive therapy. Observational studies demonstrate that patients with resistant hypertension experience a higher rate of cardiovascular and renal target organ damage such as left ventricular hypertrophy, microalbuminuria, and renal insufficiency and more cardiovascular disease (CVD) events than patients whose hypertension is well-controlled. Additionally, resistant hypertension patients may be subjected to the considerable expense of multiple office visits, diagnostic testing for secondary causes of hypertension, and referral to hypertension specialists. Because multiple factors can contribute to resistant hypertension, an explicit, sequential approach to evaluation and management is essential to optimize blood pressure, reduce cardiorenal morbidity and mortality, and avoid unnecessary expense. A number of observational studies have suggested the potential efficacy of both spironolactone and amiloride when added to a 3 drug antihypertensive regimen, but to date no randomized study has directly compared the two agents. The goal of this study is to determine whether spironolactone or amiloride is the more effective fourth agent to add to a three drug regimen in patients with resistant hypertension.
m/a
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hypertension
  • Drug: spironolactone
    tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
    Other Name: aldactone
  • Drug: amiloride
    amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
    Other Name: midamor
  • Active Comparator: 1
    this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and spironolactone will be added (dose range 12.5mg-50mg)
    Intervention: Drug: spironolactone
  • Active Comparator: 2
    this arm will include patients with resistant hypertension who are on 3 reasonably dosed agents (one being an appropriately dosed diuretic) and amiloride will be added (dose range 2.5-10mg)
    Intervention: Drug: amiloride

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
80
November 2010
October 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants will be selected from a broad range of medical clinics at the Salt Lake City VA Medical Center and surrounding community based outpatient clinics (CBOCs).
  • The participants will be referred to a resistant hypertension clinic by either their primary care provider or by a subspecialist. The referrals are made via a computerized system that is used in the Veterans Affairs Medical Center (VA) called Computerized Patient Record System (CPRS).
  • Patients are referred if their blood pressure is above goal as defined by JNC 7 and they are on 3 antihypertensive medications with one of the agents being a diuretic.
  • All patients age 18 -80 years old.

Exclusion Criteria:

  • Patients that will be excluded from the study if they have had a documented adverse reaction to either spironolactone or amiloride.
  • diagnosis of primary hyperaldosteronism
  • inability to adhere to frequent laboratory monitoring
  • estimated glomerular filtration rate (GFR) < 45 ml/min/1.73m2
  • baseline serum potassium above 5.0 mEq/L
  • type 4 renal tubular acidosis
  • pregnancy
  • heart failure that meets criteria for using either eplerenone or spironolactone
  • current unstable renal function
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00709137
IRB_00027466
Yes
Not Provided
Not Provided
Richard Rose, VA Salt Lake City Health Care System
VA Salt Lake City Health Care System
Not Provided
Principal Investigator: Richard S Rose, MD Univ of Utah Division of General Internal Medicine; VAMC SLC Internal Medicine
VA Salt Lake City Health Care System
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP